The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity constraints that have dogged its core business.
Edwards shrugs off tariffs, backs 2025 profit forecast Read More »
Despite a dip in sales and a recent schizophrenia stumble, the company drew an optimistic outlook for sales for the rest of the year, even as the specter of pharmaceutical tariffs looms.
BMS Reports Mixed Earnings as Growth Portfolio Makes Up for Generic Pressure Read More »
It’s the largest healthcare breach reported to federal regulators so far this year.
Data breach at Yale New Haven Health impacts 5.6M people Read More »
Merck, Bristol Myers Squibb, Sanofi and Roche had little clarity on the potential impact of President Donald Trump’s pharmaceutical tariffs but many companies are already preparing for what’s to come.
Tariff Uncertainty Reigns Over Q1 Earnings, With Merck Taking $200M Blow So Far Read More »
The company is planning manufacturing footprint changes, supply chain adjustments, surcharges and cost cutting to limit the impact of the tariffs.
Danaher predicts $350M tariff hit, moves to mitigate impact on profits Read More »
¿Es peligrosa la blefaroplastia? ¿Los resultados de esta cirugía pueden llegar a ser antinaturales? ¿Es lenta la recuperación? Estos conceptos erróneos confunden y preocupan a las personas que quieren mejorar la apariencia y la funcionalidad de sus …
Top 5 mitos sobre la blefaroplastia que debes conocer Read More »
Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address autoimmune diseases.
Novartis-, Sanofi-Backed Granite Brings $100M to Compete in Crowded I&I Space Read More »
The tradipitant saga stretches back to September 2024, when the FDA declined to approve Vanda’s drug in gastroparesis, a stomach condition characterized by delayed gastric emptying.
Vanda Escalates Vendetta Against FDA, Blasts ‘Bureaucrats’ For Delaying Stomach Drug Read More »
The FDA is asking Novavax for a non-mandatory postmarketing commitment to produce additional clinical data for its investigational COVID-19 vaccine.
After Missed Decision Deadline, Novavax Says COVID-19 Shot ‘Approvable’ Read More »
With a new raise provided by Flagship Pioneering, the new company is aiming to find “the silent window” before disease symptoms set in.
Etiome Steps Out of Stealth with $50M to Address Disease At The ‘Silent Stage’ Read More »
